Vasculitis & polymyalgia rheumatica

AYLo study–elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome

Ann Rheum DisPublished Prospective cohort study

Authors' conclusion

This study is the first to identify mLOY as a strong, independent predictor of relapse risk and to link mLOY with modulated proinflammatory signalling in GCA.

Study context

Population
Patients diagnosed with giant cell arteritis (GCA), prospectively recruited (mean age 76.0 years, SD 10.7)19/74 active disease at inclusion
Participants
74 patients
Exposure
mLOY >10.2% vs mLOY ≤10.2%
Outcome
Prevalence of mLOY in GCA and its impact on disease activity (relapse)
Methodological detailsprospective recruitment, ROC curve and Youden index threshold, Kaplan-Meier analysis with log-rank test, multivariable Cox regression
  • Prospective recruitment
  • ROC curve and Youden index threshold
  • Kaplan-Meier analysis with log-rank test
  • Multivariable Cox regression

Main finding

Relapse

Hazard ratio

17.4

95% CI 3.5–86.0

P = 0.003

By group

mLOY >10.2%vs mLOY ≤10.2%
HR 17.4 (95% CI 3.5–86.0); P = 0.003

As reported in the abstract

Relapses occurred in the cohort
23.0%
Median mLOY burden (SD 23.7%)
17.8%
Optimal threshold for predicting relapse
10.2%

Observational data: associations, not effects.

Further findings

mLOY and IL-6 across the cohort

mLOY positively associated with IL-6, r = 0.24
P = 0.045
Elevated IL-6 in remission patients with mLOY >10.2%
P = 0.010

mLOY and cytokines in patients on IL-6R inhibitor and in remission

mLOY positively associated with IL-6, r = 0.54
P = 0.002
mLOY positively associated with IL-17A, r = 0.40
P = 0.026

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

AYLo study–elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome. Ann Rheum Dis. Published 15 July 2025. doi:10.1016/j.ard.2025.06.2133

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.